|Day Low/High||65.44 / 66.32|
|52 Wk Low/High||55.06 / 68.12|
Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.
Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.
Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.
U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.
Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.
Biotech investors should keep a close eye on the progress in this huge potential market.
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Jim Cramer is bullish on EQT Midstream Partners, AbbVie, Blackstone Group, and Core Civic.
Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.
- New data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment(1)
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
- Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The maker of the EpiPen seems incapable of overcoming its troubles.
It's pretty normal to have profit-taking after such a strong first quarter.
Subscribers to Dividend Stock Advisor will now receive Income Seeker, our newest premium product.
- HUMIRA is now the first-and-only biologic treatment with fingernail psoriasis data in its U.S. prescribing information for moderate to severe chronic plaque psoriasis patients
Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.
Avatar Program Offers Potential for Key Discoveries of Nearly 20 Tumor Types and Biomarkers, Increased Patient Recruitment for Clinical Trials Nationwide